EUVIMEDScopri EUVIMED
Vergleichsstudie

Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes

Manijeh Noori, Evald Høj Christiansen iD, Mikkel Hougaard, Ashkan Eftekhari iD, Lars Jakobsen iD, Julia Ellert, Rebekka Vibjerg Jensen, Kirstine Nørregaard Hansen, Nicolaj Brejnholt Støttrup, Bent Raungaard, Jens Flensted Lassen, Johnny Kahlert and 2 more

Catheterization and Cardiovascular Interventions · 2026-05 · 107 (6) · 1853-1865

DOI: 10.1002/ccd.70549 ↗

At a glance

Vergleichsstudie in Catheterization and Cardiovascular Interventions, published online on 2026-03-09. Written by Manijeh Noori and 13 co-authors. Institution: Department of Cardiology, Odense University Hospital, Odense, Denmark. Major MEDLINE topics: Sirolimus, Acute Coronary Syndrome, Drug-Eluting Stents, Absorbable Implants. 32 references. Funded by: Biotronik, Bülach, Switzerland, Biosensors, Morges, Switzerland.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

The polymer‐free biolimus A9‐coated BioFreedom stent (BF‐BCS) releases a lipophilic drug that may provide a potent anti‐inflammatory effect in patients with acute coronary syndromes (ACS). Five‐year efficacy and safety of BF‐BCS were compared to the ultrathin strut biodegradable polymer sirolimus‐eluting Orsiro stent (O‐SES) in ACS patients.

Methods

From SORT OUT IX, 1672 ACS patients were analyzed (821 treated with BF‐BCS and 851 with O‐SES); 764 (46%) presented with ST‐segment‐elevation myocardial infarction (STEMI) and 907 (54%) with non‐STEMI. Endpoints were target lesion failure (TLF) (a composite of cardiac death, target lesion myocardial infarction [MI], target lesion revascularization [TLR]) and definite stent thrombosis (ST) at 5‐years.

Results

At 5‐years, TLF in ACS patients did not differ significantly between BF‐BCS and O‐SES (12.5% vs. 10.8%; rate ratio (RR) 1.12; 95% confidence interval (CI): 0.84–1.49). Cardiac death, target lesion MI, and definite ST rates were similar. TLR was higher with BF‐BCS compared to O‐SES within the first year (2.9% vs. 1.2%, RR 2.37; 95% CI: 1.13–4.99), but this difference was not maintained at 5‐year follow‐up (6.2% vs. 4.3%; RR 1.42; 95% CI: 0.92–2.18). The increased risk of TLR within the first year was driven by increased risk of TLR in STEMI patients treated with BF‐BCS compared to O‐SES (2.5% vs. 0.3%, RR 9.96; 95% CI: 1.26–79.0), while there were no differences in TLR rates in NSTEMI patients.

Conclusion

At 5‐year follow‐up, TLF did not differ significantly in BF‐BCS or O‐SES treated ACS patients. The increased risk of early TLR in STEMI patients treated with BF‐BCS was not maintained at 5‐year follow‐up.

Subjects

MeSH terms (MEDLINE)

SirolimusAcute Coronary SyndromeDrug-Eluting StentsAbsorbable ImplantsCardiovascular AgentsPercutaneous Coronary InterventionST Elevation Myocardial InfarctionNon-ST Elevated Myocardial InfarctionHumansFemaleTreatment OutcomeMaleProsthesis DesignTime FactorsAgedMiddle AgedRisk FactorsCoronary ThrombosisPolymersRetrospective Studies

Author keywords

acute coronary syndromesbiodegradable sirolimuspolymer‐free biolimustarget lesion failuretarget lesion revascularization

Substances

SirolimusumirolimusCardiovascular AgentsPolymers

Authors and institutions

  • Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.

ORCID profiles: Evald Høj Christiansen, Ashkan Eftekhari, Lars Jakobsen

Funding

  • Biotronik, Bülach, Switzerland
  • Biosensors, Morges, Switzerland

Cite

APA

Noori, M., Christiansen, E. H., Hougaard, M., Eftekhari, A., Jakobsen, L., Ellert, J., Jensen, R. V., Hansen, K. N., Støttrup, N. B., Raungaard, B., Lassen, J. F., Kahlert, J., Junker, A., & Jensen, L. O. (2026). Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes. Catheterization and Cardiovascular Interventions, 107(6), 1853-1865. https://doi.org/10.1002/ccd.70549

Vancouver

Noori M, Christiansen EH, Hougaard M, Eftekhari A, Jakobsen L, Ellert J, et al. Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes. Catheterization and Cardiovascular Interventions. 2026;107(6):1853-1865. doi:10.1002/ccd.70549

BibTeX
@article{Noori2026,
  author = {Noori, Manijeh and Christiansen, Evald Høj and Hougaard, Mikkel and Eftekhari, Ashkan and Jakobsen, Lars and Ellert, Julia and Jensen, Rebekka Vibjerg and Hansen, Kirstine Nørregaard and Støttrup, Nicolaj Brejnholt and Raungaard, Bent and Lassen, Jens Flensted and Kahlert, Johnny and Junker, Anders and Jensen, Lisette Okkels},
  title = {Long‐Term Outcomes After Percutaneous Coronary Intervention With the Polymer‐Free Biolimus‐Coated BioFreedom Stent Versus the Biodegradable‐Polymer Sirolimus‐Eluting Orsiro Stent in Patients With Acute Coronary Syndromes},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {107},
  number = {6},
  pages = {1853--1865},
  doi = {10.1002/ccd.70549}
}
Start for free →